Viking Therapeutics exhibits a beta of 0.65, implying its shares are 35% less volatile than the S&P 500. This relative stability can appeal to investors seeking exposure to the biotech sector with moderated market sensitivity. Over the past 12 months, its share movements have deviated less from broader market swings compared to peers with higher betas, potentially reducing downside risk during turbulent equity markets.

According to MarketBeat data, Viking Therapeutics has received 1 sell rating, 3 hold ratings, 9 buy ratings and 3 strong-buy ratings, yielding a consensus score of 2.88 out of 5. Analysts have set a consensus target price of $87.14, suggesting a potential upside of approximately 147% from current levels. This favorable outlook reflects confidence in the company’s clinical pipeline and long-term growth prospects.

Institutional investors own 76.0% of Viking Therapeutics’ shares, indicating substantial backing from hedge funds, mutual funds and large asset managers. Insider ownership stands at 4.1%, aligning management’s interests with those of public shareholders without excessive insider concentration. High institutional participation signals market confidence in the company’s strategy and governance.

Viking Therapeutics reported a net loss of $109.96 million last year, translating to an EPS of –$2.12 and an unwound P/E ratio of –16.66. Return on equity stood at –29.35% and return on assets at –28.41%. Despite current unprofitability, the company’s lead candidate, VK2809, is in Phase IIb trials for non-alcoholic steatohepatitis, while VK5211 advances in Phase II for post-hip fracture recovery. Additional programs include a Phase IIb-ready diabetes candidate (VK0612) and early-stage GLP dual agonist (VK2735). Investors are weighing these developmental catalysts against existing cash burn and near-term financing needs.